Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

COVID-19 Vaccine Now Available for Ages 5-11 at Cohen Children’s Medical Center

Children ages 5-11 and their parents are one step closer to ending the pandemic after Cohen Children’s Medical Center today began offering Pfizer-BioNTech’s kid-size coronavirus disease 2019 (COVID-19) vaccine. The Center for Disease Control and Prevention signed off on the latest age group to be vaccinated – representing 28 million Americans – and clearing the way for the families of seven youngsters to be the first at Northwell Health.

The patients and their parents, many of whom are physicians at the hospital, were greeted by Charles Schleien, MD, senior vice president and chair of pediatrics at Northwell Health and Cohen Children’s. Noting that this vaccination was a big step toward protecting those who are eligible, Dr. Schleien said, “In New York, six in 10 kids who are 12-and-over are already vaccinated. We need to get that number higher – and starting today, we need to chip away at vaccinating the newest group of eligible children. The vaccine is safe. It works – and it will be the way we successfully lower COVID stats across the region, nation and world.”

Sophia Jan, MD, chief of general pediatrics at Cohen Children’s, was on hand to vaccinate the youngsters and offer her support to their parents. “Being vaccinated will make it so much easier for our youngsters to get back to their normal lives,” said Dr. Jan. “Not only will they be able to get back to school and enjoy the holidays, but the important things – like hugging their parents and visiting their grandparents – we can start thinking about these things again.”

When interviewed as a group by a roomful of reporters, the newly vaccinated children all agreed that a moment of discomfort was well worth the relief of staying virus free. “Maybe one day we can go to school without masks,” they said.

In an effort to provide vaccinations to this newest eligible group, Northwell Health has established vaccination pods in Manhattan, Queens, Long Island and Westchester County. Locations and hours are:

  • Nassau County: (1 Marcus Ave, New Hyde Park, NY) Nov. 7 & 14, 9 a.m.-5 p.m.
  • Suffolk County: (5181 Sunrise Highway, Bohemia, NY) Nov. 6 & 13, 9 a.m.-5 p.m.
  • Suffolk County: (284 Pulaski Road, Greenlawn, NY) Nov. 11, 8 a.m.-8 p.m.; Nov. 18, Noon-8 p.m.
  • Suffolk County: (4 West 2nd Street, Riverhead, NY) Nov. 7 & 14, 9 a.m.-5 p.m.
  • Manhattan: (200 West 13th Street, New York, NY) Nov. 10, 3-7 p.m.; Nov. 13, 10 a.m.-3 p.m.
  • Queens: (95-25 Queens Blvd., Rego Park, NY) Nov. 6 & 13, 9 a.m.-9 p.m.
  • Westchester County: (480 North Bedford Road, Chappaqua, NY) Nov. 7 & 14, 9 a.m.-5 p.m.

To schedule a vaccine appointment, call (844) 919-VACC for the most up-to-date availability or go to:




Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy